Literature DB >> 11274226

Temporary treatment of prepubescent rats with angiotensin inhibitors suppresses the development of hypertensive nephrosclerosis.

Hideaki Nakaya1, Hiroyuki Sasamura1, Matsuhiko Hayashi1, Takao Saruta1.   

Abstract

Hypertensive nephrosclerosis is a leading cause of end-stage renal disease; therefore, strategies to prevent the development of renal disease require close study. Here it is demonstrated that transient treatment of prepubescent rats with angiotensin inhibitors attenuated their susceptibility to the development of hypertensive nephrosclerosis after maturation. Stroke-prone spontaneously hypertensive Izumo strain rats were divided into four groups, treated with vehicle, the angiotensin-converting enzyme inhibitor (ACEI) delapril (40 mg/kg per d), the angiotensin receptor antagonist (AT1R-Ant) candesartan cilexetil (1 mg/kg per d), or the vasodilator hydralazine (25 mg/kg per d) from weaning to puberty (3 to 10 wk of age), and then monitored without treatment for 6 mo. BP in the ACEI- and AT1R-Ant-treated groups remained significantly decreased, compared with the untreated and hydralazine-treated groups. Moreover, marked proteinuria and nephrosclerosis developed in the untreated and hydralazine-treated groups at 30 wk but were suppressed in the ACEI- and AT1R-Ant-treated groups. Of interest, plasma renin activity, plasma angiotensin II concentrations, and renal renin mRNA levels were reduced by >50% in the ACEI- and AT1R-Ant-treated rats, suggesting that the treatments may have attenuated the development of nephrosclerosis by overcoming the susceptibility of stroke-prone spontaneously hypertensive rats to overactivation of the renin-angiotensin system.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11274226     DOI: 10.1681/ASN.V124659

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  8 in total

Review 1.  Clinical significance of 'cardiometabolic memory': a systematic review of randomized controlled trials.

Authors:  Hiroshi Itoh; Isao Kurihara; Kazutoshi Miyashita; Masami Tanaka
Journal:  Hypertens Res       Date:  2017-01-19       Impact factor: 3.872

2.  Angiotensin II type 2 receptor stimulation with compound 21 improves neurological function after stroke in female rats: a pilot study.

Authors:  Wael Eldahshan; Tauheed Ishrat; Bindu Pillai; Mohammed A Sayed; Abdulrahman Alwhaibi; Abdelrahman Y Fouda; Adviye Ergul; Susan C Fagan
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-03-01       Impact factor: 4.733

3.  Renal T cell infiltration occurs despite attenuation of development of hypertension with hydralazine in Envigo's female Dahl rat maintained on a low-Na+ diet.

Authors:  Amrita V Pai; Crystal A West; Aline M Arlindo de Souza; Parnika S Kadam; Emma J Pollner; David A West; Jia Li; Hong Ji; Xie Wu; Michelle J Zhu; Chris Baylis; Kathryn Sandberg
Journal:  Am J Physiol Renal Physiol       Date:  2019-06-26

4.  Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats.

Authors:  Yukiko Nagai; Li Yao; Hiroyuki Kobori; Kayoko Miyata; Yuri Ozawa; Akira Miyatake; Tokihito Yukimura; Takatomi Shokoji; Shoji Kimura; Hideyasu Kiyomoto; Masakazu Kohno; Youichi Abe; Akira Nishiyama
Journal:  J Am Soc Nephrol       Date:  2005-01-12       Impact factor: 10.121

Review 5.  Should the results of TROPHY affect the JNC 7 definition of prehypertension?

Authors:  Stevo Julius
Journal:  Curr Hypertens Rep       Date:  2007-06       Impact factor: 5.369

6.  The SSLepR mutant rat represents a novel model to study obesity-induced renal injury before puberty.

Authors:  Bibek Poudel; Corbin A Shields; Ubong S Ekperikpe; Andrea K Brown; Olivia K Travis; Jordan C Maury; Sarah Fitzgerald; Stanley V Smith; Denise C Cornelius; Jan M Williams
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2022-02-02       Impact factor: 3.619

7.  The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) observational follow-up study: benefits of RAS blockade with olmesartan treatment are sustained after study discontinuation.

Authors:  Jan Menne; Eberhard Ritz; Luis M Ruilope; Christos Chatzikyrkou; Giancarlo Viberti; Hermann Haller
Journal:  J Am Heart Assoc       Date:  2014       Impact factor: 5.501

8.  Activation of the intestinal tissue renin-angiotensin system by transient sodium loading in salt-sensitive rats.

Authors:  Masaki Ryuzaki; Kazutoshi Miyashita; Masaaki Sato; Hiroyuki Inoue; Kentaro Fujii; Aika Hagiwara; Asuka Uto; Sho Endo; Takuma Oshida; Kenichiro Kinouchi; Hiroshi Itoh
Journal:  J Hypertens       Date:  2022-01-01       Impact factor: 4.844

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.